Personalized mRNA cancer vaccine clears Phase 3 hurdle in melanoma
A patient-specific mRNA vaccine (intismeran autogene) combined with Keytruda met the Phase 3 primary endpoint in a 1,137-patient trial of resected melanoma, improving recurrence-free survival and potentially paving the way for the first FDA-approved mRNA-based cancer therapy; full data are to be presented later, with safety profile consistent with Keytruda.